Assessment of tolerance and efficacy of 2nd line S-1 therapy after 1st line GEM for unresectable pancreatic cancer patients

Assessment of tolerance and efficacy of 2nd line S-1 therapy after 1st line GEM for unresectable pancreatic cancer patients - 2nd line S-1 after 1st line GEM for unresectable pancreatic cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000834

Enrollment

Registered

2007-09-28

Start date

2007-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Anti-cancer drug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: unresectable pancreatic cancer after 1st line therapy of GEM

Exclusion criteria

Exclusion criteria: 1. ascites 2. Myocardiac infarction in the past 3 months 3. Uncontrolled Diabetes Melitus etc

Design outcomes

Primary

Measure	Time frame
Completion rate	—

Countries

Japan

Contacts

Public ContactYoshiki Hirooka

Nagoya University Hospital Department of Endoscopy

052-744-2602

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026